Key facts
- This page summarizes Zohar Daphne's Form 3 filing for Seaport Therapeutics, Inc. (SPTX).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 30 Apr 2026, 20:17.
Zohar Daphne - 30 Apr 2026 Form 3 Insider Report for Seaport Therapeutics, Inc. (SPTX)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- SPTX
- Reported as of
- 30 Apr 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Lana Gladstein, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Zohar Daphne filed Form 3 for Seaport Therapeutics, Inc. (SPTX) on 30 Apr 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001727388
Primary reporting owner
Zohar Daphne
- Relationship
- Chief Executive Officer, Director
- Address
- SEAPORT THERAPEUTICS, INC., 101 SEAPORT BLVD., FLOOR 12, BOSTON
- Signature
- /s/ Lana Gladstein, Attorney-in-Fact
- Signature date
- 30 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,194,001
- Date
- 30 Apr 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,311,259
- Exercise price
- $3.05
- Footnotes
- F1
SPTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 182,485
- Exercise price
- $7.39
- Footnotes
- F2
SPTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 30 Apr 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 271,813
- Exercise price
- $10.31
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
1/18th of the shares underlying this option vested and became exercisable on April 16, 2024, with the remaining shares vesting in thirty-four (34) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F2
The shares underlying this option vest and become exercisable in thirty-six (36) equal monthly installments following April 16, 2024, subject to the Reporting Person's continued service on each such vesting date.
Footnote F3
The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.
SEC remarks
Exhibit 24 - Power of Attorney